Performance of laboratories in antimicrobial susceptibility testing of MB-16-07
Antibiotics | MIC | Antibiotics | Disk | ||||||
---|---|---|---|---|---|---|---|---|---|
S | I | R | IND | S | I | R | IND | ||
CLSI group A | |||||||||
Ampicillin | 200 | Ampicillin | 23 | ||||||
Cefotaxime | 204 | 1 | Cefotaxime | 17 | |||||
Ceftazidime | 175 | Ceftazidime | 12 | ||||||
Ceftriaxone | 1 | Ceftriaxone | 10 | ||||||
Ciprofloxacin | 165 | 1 | 2 | Ciprofloxacin | 35 | ||||
Levofloxacin | 37 | 1 | Levofloxacin | 4 | |||||
Trimethoprim/Sulfamethoxa | 204 | Trimethoprim/Sulfamethoxa | 24 | ||||||
Other CLSI groups | |||||||||
Amoxicillin/Clavulanic acid | 12 | Amoxicillin/Clavulanic acid | 4 | ||||||
Aztreonam | 7 | Aztreonam | 4 | ||||||
Cefepime | 37 | Cefepime | 5 | ||||||
Chloramphenicol | 3 | Chloramphenicol | 5 | ||||||
Clinafloxacin | 1 | Imipenem | 10 | ||||||
Ertapenem | 15 | Meropenem | 6 | ||||||
Imipenem | 23 | Ofloxacin | 1 | ||||||
Meropenem | 11 | Piperacillin | 2 | 2 | |||||
Minocycline | 1 | 2 | Piperacillin/Tazobactam | 6 | |||||
Piperacillin | 6 | ||||||||
Piperacillin/Tazobactam | 21 | ||||||||
Ticarcillin/Clavulanic acid | 1 | 1 | 1 | ||||||
Unacceptable | |||||||||
Amikacin | 8 | Amikacin | 10 | ||||||
Cefazolin | 9 | Carbenicillin | 1 | ||||||
Cefoxitin | 4 | Cefazolin | 4 | ||||||
Gentamicin | 13 | Cefmetazole | 1 | ||||||
Tigecycline | 5 | Cefoxitin | 2 | ||||||
Tobramycin | 1 | Cefuroxime axetil | 1 | ||||||
Cefuroxime sodium | 1 | ||||||||
Gentamicin | 2 | 7 | |||||||
Netilmicin | 1 | ||||||||
Rifampin | 1 | ||||||||
Tigecycline | 1 | ||||||||
Tobramycin | 3 | ||||||||
IND | |||||||||
Ampicillin/Sulbactam | 2 | 7 | Ampicillin/Sulbactam | 3 | 1 | 1 | |||
Colistin | 2 | Cefoperazone/Sulbactam | 1 | ||||||
Nalidixic acid | 1 | Moxifloxacin | 1 | ||||||
Nalidixic acid | 2 |
Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistance; IND, indeterminate; CLSI, Clinical and Laboratory Standards Institute.